CClinicalTrials.gg
RecruitingNCT06104059NOLGADELSUpdated Apr 3, 2025

NOL Guided Analgesia During Elective Laparoscopic Surgery Under General Anesthesia

An interventional study of Nociception level index (NOL™) and Fentanyl in Intraoperative Analgesia, sponsored by Attikon Hospital. Recruiting at 1 site in Greece. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Attikon Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Apr 2023, registered Oct 2023).
  • Started Apr 2023; still recruiting 3 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of this study is to investigate the hypothesis that the intraoperative use of the nociception level index NOL can reduce opioid consumption in adult patients undergoing elective laparoscopic surgeries under general anesthesia, as well as to explore its effect on post-operative pain and patient recovery.

Read the detailed description

The study is a Prospective Randomized clinical trial. Adult patients (>18y) undergoing elective laparoscopic surgery under general anesthesia will be included.

The patients will be randomized using the "sealed envelope" randomization method into two groups.

Intervention group: in this group, the nociception level index NOL will be used in order to guide intraoperative analgesia. Control group: in this group standard anesthetic care will be provided. Analgesic demands will be treated with bolus doses of iv fentanyl.

All patients will receive the same general anesthesia induction regimen. Patients upon entering the operating room will have standard monitoring applied [Noninvasive Blood Pressure (NIBP), ECG, SpO2] and a venous line placed. The depth of anesthesia will also be monitored by using the BIS sensor and placement of the NOL sensor. Specifically, a sensor (Covidien, BIS™ monitoring system with 3.50 software) will be placed on the forehead (after cleaning with an rubbing alcohol solution) and an NOL sensor (Medasense Biometrics Ltd., PMD200™) on a finger on the opposite upper extremity to that on which the blood pressure cuff will beplaced. Neuromuscular blockade will also be monitored using a neurostimulator (Organon, TOF-Watch SX) to stimulate and record the response of the ulnar nerve to TOF. Before induction to general anesthesia, all patients receive an IV bolus 1mg of midazolam and preoxygenation is performed for 5 minutes with a mask (FiO2: 100%, FGF: 12 l/min). Induction to general anesthesia will be performed with propofol 2.5mg/kg iv and fentanyl 2mcg/kg iv and once a BIS \<60 is achieved, rocuronium 0.6mg/kg iv will be administered. At the same time, the patient's ventilation is supported with a mask and bag (FiO2:100%). When TOF=0, endotracheal intubation will be performed. After intubation, maintenance of anesthesia will be achieved by administration of sevoflurane 0.7 MAC in 50% O2/Air and co-administration of iv propofol infusion (75-150mcg/kg/min) with target BIS: 40-60. Subsequently, 8 mg iv dexamethasone and 0.1 mg/kg iv morphine will be administered and an arterial catheter is placed for continuous blood pressure measurement. Before the surgical incision, fentanyl IV 1.5mcg/kg will be administered and the surgical incisions will be infiltrated with a 0.375% ropivacaine solution of 20ml. Intraoperatively, to achieve optimal analgesia, iv fentanyl will be administered according to the group to which the patient has been allocated, as described above. Half an hour before the end of the operation, 1g paracetamol iv and 4mg ondasetron iv will be administered and 20 minutes before the end of the surgical procedure, the propofol infusion will stop.

Reversal of peripheral neuromuscular blockade will be perfomed using sugammadex: 2-4mg/kg, depending on the indication of the neurostimulator. The patient will be extubated if TOF=4 \& TOF ratio ≥0.9 and BIS >80. Subsequently, the patient will be transferred to the Post Anesthesia Care Unit (PACU).

In PACU, intensity of postoperative pain will be assessed every 15 minutes with the Visual analogue scale (VAS, 0-10) and for a score >4, morphine 1mg iv bolus will be administered (up to 0.15mg/kg morphine in total for each patient including the intraoperative dose) until the patient is released from PACU.

Patient recovery will be assessed using the Post Anesthesia Recovery Score (PAR-Score), i.e. the Modified Aldrete score initially as soon as the patient is transferred to the PACU and patients will be released from PACU once they have score ≥9. The length of stay in the PACU until a score ≥9 is reached will also be recorded.

Any events or adverse effects (respiratory depression, lethargy, nausea, vomiting, itching, etc.) will also be recorded in the PACU.

02

Conditions studied

  • Intraoperative Analgesia
03

In context

Lead sponsor

Attikon Hospital is the lead sponsor of 83 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult patients undergoing planned laparoscopic surgery under general anesthesia.

Exclusion criteria

Exclusion Criteria:

  • Emergency surgery.
  • Pregnancy.
  • Drug or alcohol abuse in the last 6 months.
  • Chronic opioid use or patients with chronic pain.
  • Serious comorbidity [cardiac disease (atrial fibrillation, ventricular arrhythmias), liver or kidney disease]
  • Obesity (BMI >35).
  • Permanently implanted pacemaker.
  • Patients with CNS disease.
  • Allergy to any of the study drugs.
  • Patients receiving anticholinergics agonists, α2-adrenergic agonists, β1-adrenergic antagonists, antiarrhythmic drugs.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Nociception level index (NOL™)

    The nociception level index NOL will be used in order to quide intraopertaive analgesia.

    Device: Nociception level index (NOL™)

  • Active comparator
    Standard of care

    Intraoperative analgesia will be based on common practice, i.e. changes in hemodynamic parameters.

    Other: Fentanyl

Interventions

  • DeviceNociception level index (NOL™)

    If a NOL value \>25 persists for \>1 minute a bolus of iv fentanyl 0.5mcg/kg will be given and reassessment of the NOL value will continue every 5 minutes. If NOL index value: 10-25 is not reached within 10 minutes, fentanyl 0.5mcg/kg iv is re-administered.

  • OtherFentanyl

    Bolus doses of iv fentanyl 0.5 mcg/kg will be administered based on the judgment of the anesthesiologist in charge.

06

What researchers measure

Primary outcomes

  1. Intraoperative total consumption of opioids

    Intraoperative total consumption of opioids will be calculated in all patients.

    Time frame: Up to 30 minutes after the end of operation

Secondary outcomes

  1. Postoperative administration of opioids in PACU

    Total consumption of opioids will be calculated in all patients

    Time frame: Until the patient is released from PACU (up to 24 hours)

  2. Intensity of postoperative pain in PACU

    In PACU, intensity of postoperative pain will be assessed every 15 minutes with the Visual analogue scale, a 10 points scale (0= no pain and 10= worst pain)

    Time frame: Until the patient is released from PACU (up to 24 hours)

07

Study locations

1 of 1 sites recruiting
  • 2nd Department of Anesthesiology, Attikon University Hospital
    Athens, Attiki 12462, Greece
    • Paraskevi Matsota, Prof · Contact
    • Paraskevi Mastota, MD, PhD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06104059
Lead sponsor
Attikon Hospital
Responsible party
Paraskevi Matsota (Prof of Anesthesiology, Attikon Hospital) — Principal investigator
First posted
Oct 27, 2023
Start date
Apr 20, 2023
Primary completion
Sep 20, 2025 (estimated)
Completion
Sep 20, 2026 (estimated)
Last update
Apr 3, 2025

Study contacts

PARASKEVI Prof MATSOTA
Contact
matsota@yahoo.gr
6945544563

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion